OQRO

Daily notes / October 19, 2026

Orin Hirschman filed a Schedule 13G reporting a Kyverna Therapeutics stake

Written by a model from the facts OQRO holds and checked against them, sentence by sentence of . Published . 2 min read.

Tall office buildings around Trinity Church in lower Manhattan seen from above, with the church spire between the towers.
Skyscrapers around Trinity Church, New York, 1905. Photo: Detroit Publishing Company (scan by the New York Public Library), Public domain (scan of a 1905 photograph, New York Public Library Digital Collections). Original

The short answer

Orin Hirschman filed a Schedule 13G on Oct 19, 2026, reporting ownership of 3,650,000 shares, or 5.9% of Kyverna Therapeutics (KYTX). The filing is an ownership report, not a record of when shares were bought. Other public records around the filing include company news, a clinical trial update, short-interest data and reported share prices.

What did Orin Hirschman report?

The SEC Schedule 13G filed on Oct 19, 2026 reports that Orin Hirschman held 3,650,000 shares, equal to 5.9% of the class of Kyverna Therapeutics (KYTX).

A Schedule 13G reports ownership. It does not identify the date shares were bought, so the filing alone does not establish when the reported position was acquired.

How does the filing date relate to company results?

The filing came 50 days after Kyverna Therapeutics announced results on Aug 11, 2026, in an 8-K Item 2.02. That timing places the ownership filing after the results announcement, but the records do not establish a connection between them.

What company and market records are available?

ClinicalTrials.gov shows 1 study sponsored by the company updated in the period. The latest, Study NCT06193889, is titled “KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myastheni...” It is a Phase 2/3 study with recruiting status, was updated on Jul 29, 2026, and lists primary completion for 2027-09.

FINRA short-interest data for KYTX on the settlement date of Sep 30, 2026, showed 9,618,412 shares, up 9.72% on the previous report, or about 8.85 days of average volume.

For the quarter ended Jun 30, 2026, 13F filings showed Simplify Asset Management Inc. increased its position by 9,497 shares and Susquehanna Portfolio Strategies, LLC increased its position by 60,999 shares. Jacobs Levy Equity Management, Inc and Omers Administration Corp were listed as sold out. A 13F is a quarter-end snapshot with no trade date.

What news and share prices were reported around the filing?

Finnhub listed Yahoo coverage on Oct 7, 2026, titled “Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026.” It also listed Benzinga coverage that day, titled “Kyverna Therapeutics To Demonstrate Two Abstracts For Presentation At MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting.”

KYTX closed at $6.80 on Sep 30, 2026, the last session on or before the filing date. From Aug 31, 2026 to Sep 30, 2026, the close moved from $8.48 to $6.80, a change of −19.8%. From Sep 30, 2026 to Oct 19, 2026, the close moved from $6.80 to $5.83, a change of −14.3%.

What this does not tell you?

A Schedule 13D or 13G is an ownership filing, not a trade record, and it does not say when shares were bought. The share-price moves are context only; the filing does not explain them, and other news can move a price.

The press headlines are listed as published by the outlets; OQRO has not checked them and does not summarize the articles. This describes public filings and is not investment advice. For more company filing context, see Kyverna Therapeutics on OQRO.

Sources

A model wrote this page from the facts OQRO holds; every number, date, name and link in it was checked against those facts before publication, and a text that failed the check was not published. It describes what was filed, not why, and it is not investment advice. How OQRO treats data

Explore the data

More daily notes